Effects of IL17/23 Inhibitors on Markers of Subclinical Atherosclerosis in Patients with Psoriasis: An Observational Study.

IF 4.2 3区医学 Q1 DERMATOLOGY

Dermatology and Therapy Pub Date : 2025-10-08 DOI:10.1007/s13555-025-01549-1

Aikaterini Tsiogka, Stergios Soulaidopoulos, Stamatios Gregoriou, Natalia Rompoti, Pantelis Panagakis, Marina Papoutsaki, Panagiotis Kostakis, George Kontochristopoulos, Konstantinos Tsioufis, Charalambos Vlachopoulos, Alexander Stratigos, Dimitrios Rigopoulos

{"title":"Effects of IL17/23 Inhibitors on Markers of Subclinical Atherosclerosis in Patients with Psoriasis: An Observational Study.","authors":"Aikaterini Tsiogka, Stergios Soulaidopoulos, Stamatios Gregoriou, Natalia Rompoti, Pantelis Panagakis, Marina Papoutsaki, Panagiotis Kostakis, George Kontochristopoulos, Konstantinos Tsioufis, Charalambos Vlachopoulos, Alexander Stratigos, Dimitrios Rigopoulos","doi":"10.1007/s13555-025-01549-1","DOIUrl":null,"url":null,"abstract":"Introduction: To date, several reports demonstrated improved markers of subclinical atherosclerosis in patients with psoriasis treated with biologics. However, data on the antiatherogenic effect of IL23 inhibitors are sparse. Herein, we sought to assess the impact of 1-year treatment with an interleukin (IL)-17 or IL-23 inhibitor on arterial stiffness in patients with moderate-to-severe psoriasis.Methods: This observational cohort study included patients with moderate-to-severe psoriasis treated with either an IL-17 inhibitor or an IL-23 inhibitor or a conventional systemic agent/apremilast (control group) for 52 weeks. The primary outcome was the evaluation of changes in carotid-femoral pulse wave velocity (PWV) and augmentation index normalized to 75 beats/min (AIx75) after 24 and 52 weeks. Secondary outcomes were the comparison of change in PWV and AIx75 between the study groups and the assessment of psoriasis disease severity scores and in ankle-brachial index (ABI).Results: In total, 66 patients (39 male/27 female), with a mean [standard deviation (SD)] age of 56 (13.1) years, were included; 21 received an IL-17 inhibitor, 29 an IL-23 inhibitor, and 16 a conventional systemic agent or apremilast (control group). PWV and AIx75 improved in all groups at weeks 24 and 52. However, a statistically significant reduction of PWV was observed only in the IL23 group as early as at week 24 (p < 0.001). AIx75 was reduced significantly in the IL17 group at week 24 and in both IL-17 and IL-23 groups at week 52 (p < 0.001 and p = 0.014, respectively). The reduction of PWV and AIx75 at week 52 did not reach the level of statistical significance in the control group and was statistically comparable between the IL-17 and IL-23 groups.Conclusions: Both IL-23 and IL-17 inhibition exhibited comparable improvement of arterial stiffness in patients with psoriasis. Further studies are needed to evaluate the long-term impact of biologics on the cardiovascular status of these patients. Retrospectively registered ClinicalTrials.gov identifier: NCT07169682. A Graphical abstract is available for this article.","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":""},"PeriodicalIF":4.2000,"publicationDate":"2025-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Dermatology and Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s13555-025-01549-1","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"DERMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: To date, several reports demonstrated improved markers of subclinical atherosclerosis in patients with psoriasis treated with biologics. However, data on the antiatherogenic effect of IL23 inhibitors are sparse. Herein, we sought to assess the impact of 1-year treatment with an interleukin (IL)-17 or IL-23 inhibitor on arterial stiffness in patients with moderate-to-severe psoriasis.

Methods: This observational cohort study included patients with moderate-to-severe psoriasis treated with either an IL-17 inhibitor or an IL-23 inhibitor or a conventional systemic agent/apremilast (control group) for 52 weeks. The primary outcome was the evaluation of changes in carotid-femoral pulse wave velocity (PWV) and augmentation index normalized to 75 beats/min (AIx75) after 24 and 52 weeks. Secondary outcomes were the comparison of change in PWV and AIx75 between the study groups and the assessment of psoriasis disease severity scores and in ankle-brachial index (ABI).

Results: In total, 66 patients (39 male/27 female), with a mean [standard deviation (SD)] age of 56 (13.1) years, were included; 21 received an IL-17 inhibitor, 29 an IL-23 inhibitor, and 16 a conventional systemic agent or apremilast (control group). PWV and AIx75 improved in all groups at weeks 24 and 52. However, a statistically significant reduction of PWV was observed only in the IL23 group as early as at week 24 (p < 0.001). AIx75 was reduced significantly in the IL17 group at week 24 and in both IL-17 and IL-23 groups at week 52 (p < 0.001 and p = 0.014, respectively). The reduction of PWV and AIx75 at week 52 did not reach the level of statistical significance in the control group and was statistically comparable between the IL-17 and IL-23 groups.

Conclusions: Both IL-23 and IL-17 inhibition exhibited comparable improvement of arterial stiffness in patients with psoriasis. Further studies are needed to evaluate the long-term impact of biologics on the cardiovascular status of these patients. Retrospectively registered ClinicalTrials.gov identifier: NCT07169682. A Graphical abstract is available for this article.

查看原文本刊更多论文

IL17/23抑制剂对银屑病患者亚临床动脉粥样硬化标志物的影响：一项观察性研究

迄今为止，有几篇报道表明，生物制剂治疗银屑病患者的亚临床动脉粥样硬化标志物得到改善。然而，关于il - 23抑制剂抗动脉粥样硬化作用的数据很少。在此，我们试图评估1年白介素(IL)-17或IL-23抑制剂治疗对中重度牛皮癣患者动脉僵硬的影响。方法：这项观察性队列研究纳入了接受IL-17抑制剂或IL-23抑制剂或常规全身药物/阿普米司特（对照组）治疗52周的中重度银屑病患者。主要结果是评估24周和52周后颈-股脉波速度（PWV）和增强指数归一化至75次/分（AIx75）的变化。次要结果是比较研究组之间PWV和AIx75的变化以及银屑病严重程度评分和踝臂指数（ABI）的评估。结果：共纳入66例患者（男性39例/女性27例），平均[标准差（SD）]年龄56（13.1）岁；21人接受IL-17抑制剂治疗，29人接受IL-23抑制剂治疗，16人接受常规全身药物或阿普米司特治疗（对照组）。在第24周和第52周，各组PWV和AIx75均有改善。然而，早在第24周，仅在IL-23组中观察到具有统计学意义的PWV降低(p)。结论：IL-23和IL-17抑制对银屑病患者动脉僵硬的改善具有可比性。需要进一步的研究来评估生物制剂对这些患者心血管状况的长期影响。回顾性注册ClinicalTrials.gov识别码：NCT07169682。本文的图形摘要是可用的。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Dermatology and Therapy Medicine-Dermatology

CiteScore

6.00

自引率

8.80%

发文量

187

审稿时长

6 weeks

期刊介绍： Dermatology and Therapy is an international, open access, peer-reviewed, rapid publication journal (peer review in 2 weeks, published 3–4 weeks from acceptance). The journal is dedicated to the publication of high-quality clinical (all phases), observational, real-world, and health outcomes research around the discovery, development, and use of dermatological therapies. Studies relating to diagnosis, pharmacoeconomics, public health and epidemiology, quality of life, and patient care, management, and education are also encouraged. Areas of focus include, but are not limited to all clinical aspects of dermatology, such as skin pharmacology; skin development and aging; prevention, diagnosis, and management of skin disorders and melanomas; research into dermal structures and pathology; and all areas of aesthetic dermatology, including skin maintenance, dermatological surgery, and lasers. The journal is of interest to a broad audience of pharmaceutical and healthcare professionals and publishes original research, reviews, case reports/case series, trial protocols, and short communications. Dermatology and Therapy will consider all scientifically sound research be it positive, confirmatory or negative data. Submissions are welcomed whether they relate to an International and/or a country-specific audience, something that is crucially important when researchers are trying to target more specific patient populations. This inclusive approach allows the journal to assist in the dissemination of quality research, which may be considered of insufficient interest by other journals. The journal appeals to a global audience and receives submissions from all over the world.